Skip to main content

Moderna, Inc.

MRNA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001682852

In the last 90 days, Moderna, Inc. insiders filed 0 open-market purchases and 5 sales; 784 institutions reported holding it in 13F filings for Q2 2026, worth $22.3B in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $49.2M in total
5
13F holdersQ2 2026, +64 vs. previous quarter
784
13F valueReported value at the end of Q2 2026
$22.3B
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding MRNA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding MRNA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Moderna, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 16, 2026 (view filing)4:48 PM ETSep 14-152 daysHoge StephenPresidentSSale−80.6K$145.10−$11.7M−4.9%1.56M after2 lots10b5-1
Sep 14, 2026 (view filing)4:25 PM ETSep 104 daysMock James MChief Financial OfficerSSale−34.8K$134.49−$4.69M−37.0%59.4K after2 lots10b5-1
Sep 3, 2026 (view filing)4:56 PM ETSep 12 daysKlinger Shannon ThymeChief Legal OfficerSSale−3.47K$139.95−$485.8K−4.5%74.1K after10b5-1
Aug 7, 2026 (view filing)4:11 PM ETAug 52 daysBancel StephaneChief Executive OfficerSSale−499.2K$57.52−$28.7M−7.5%6.19M after4 lots10b5-1
Jul 16, 2026 (view filing)4:45 PM ETJul 151 dayHoge StephenPresidentSSale−53.3K$67.60−$3.61M−3.5%1.48M after10b5-1
Jun 17, 2026 (view filing)Jun 152 daysHoge StephenPresidentSSale−53.3K$51.37−$2.74M−3.5%1.48M after10b5-1
Jun 8, 2026 (view filing)Jun 44 daysKlinger Shannon ThymeChief Legal OfficerSSale−3.47K$50.00−$173.6K−4.9%67.5K after10b5-1
May 22, 2026 (view filing)May 211 dayAfeyan NoubarDirectorSSale−9.26K$46.84−$433.9K−70.2%3.92K after
May 18, 2026 (view filing)May 153 daysHoge StephenPresidentSSale−53.3K$48.40−$2.58M−3.5%1.48M after10b5-1
May 4, 2026 (view filing)May 13 daysHussain AbbasDirectorSSale−5.68K$46.63−$265.0K−32.0%12.1K after10b5-1

Top 10 13F holders, Q2 2026

The largest institutional positions in Moderna, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 784 holders
Institutions holding MRNA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
FMR LLC51,859,891$3.63B0.16%+6,187,867+13.5%Added
BlackRock, Inc.30,599,409$2.14B0.03%+963,533+3.3%Added
Vanguard Capital Management LLC23,208,792$1.63B0.03%+336,334+1.5%Added
Capital World Investors22,276,996$1.56B0.18%+3,579,302+19.1%Added
Baillie Gifford & Co18,206,778$1.28B1.16%−1,779,098−8.9%Reduced
State Street Corp15,726,193$1.10B0.03%+864,784+5.8%Added
Vanguard Portfolio Management LLC15,581,313$1.09B0.05%−35,054−0.2%Reduced
Geode Capital Management, LLC9,710,335$678.8M0.04%+275,203+2.9%Added
Morgan Stanley9,538,094$668.0M0.04%+1,066,831+12.6%Added
Theleme Partners LLP8,057,571$564.3M33.52%+9,326+0.1%Added